David Alan Popper, M.D. Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 301 Oxford Valley Rd, Suite 701, Yardley, PA 19067 Phone: 215-321-7221 Fax: 215-321-9109 |
Dr. Stephen Arnold Rafelson, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 301 Oxford Valley Rd, Suite 701, Yardley, PA 19067 Phone: 215-321-7221 Fax: 215-321-9109 |
Dr. Kenneth Spencer Breslin, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 301 Oxford Valley Rd, Suite 701, Yardley, PA 19067 Phone: 215-321-7221 Fax: 215-321-9109 |
Dr. Samuel Bae, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 301 Oxford Valley Rd Ste 804, Yardley, PA 19067 Phone: 215-321-4700 Fax: 215-321-9008 |
News Archive
Exalenz Bioscience, developer of advanced diagnostic systems that use a patient's breath to detect and help manage gastrointestinal and liver conditions, announced today the global launch of the BreathID Hp, a next generation device in the company's BreathID product line.
Expectant mothers who eschew asthma treatment during pregnancy heighten the risk transmitting the condition to their offspring, according to one of the largest studies of its kind published in the European Respiratory Journal.
Drug manufacturer Pfizer is coming up with a cheaper and generic version of their erectile dysfunction pill Viagra this week.
"The Peace Corps has announced a strategic partnership with the Water and Development Alliance (WADA) - a long-standing public-private partnership between the U.S. Agency for International Development (USAID) and the Coca-Cola Company (Coca-Cola) - to improve local capacity to deliver sustainable water supply, sanitation and hygiene (WASH) services for the reduction of waterborne disease around the world," a Peace Corps press release reports.
Synta Pharmaceuticals Corp. announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
› Verified 4 days ago